Human/Mouse/Rat Testican 2/SPOCK2 Alexa Fluor® 750-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # AF2328S
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
Western Blot, Immunoprecipitation
Label
Alexa Fluor 750 (Excitation = 749 nm, Emission = 775 nm)
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human Testican 2/SPOCK2
Glu23-Trp424
Accession # Q92563
Glu23-Trp424
Accession # Q92563
Specificity
Detects human, mouse, and rat Testican 2/SPOCK2 in direct ELISAs and human Testican 2/SPOCK2 in Western blots.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Applications
Application
Recommended Usage
Immunoprecipitation
Optimal dilution of this antibody should be experimentally determined.
Western Blot
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
Background: Testican 2/SPOCK2
Testican 2 (also SPOCK2) is a 60 - 140 kDa, secreted multidomain proteoglycan that belongs to the BM-40/SPARC family of extracellular proteins. It is expressed by neurons (both excitatory and GABAergic) plus brain endothelial cells, and appears to abrogate testican 1 and 3 mediated inhibition of MT1- and MT3-MMP activity. Mature human Testican 2 is 402 amino acids (aa) in length (aa 23 - 424). It contains a unique 66 aa N terminus, followed by a Kazal-like follistatin domain (aa 89-192), a collagen-binding domain (aa 210-219), a Ca++ binding region, one thyroglobulin-like segment (aa 310-376) and an acidic C-terminus that contains two potential GAG attachment sites at Ser383 and Ser388. The wide variation in native MW reflects the capabilities of differing cells to add glycan adducts to the molecule. Typically, it appears to lie belween 80-125 kDa. There are potential splice variants. One shows an alternative start site at Met110, a second shows a deletion of aa 64-66, while a third contains a 14 aa substitution for aa 64-242. Mature human Testican 2 is 94% aa identical to mouse and rat Testican 2.
Additional Testican 2/SPOCK2 Products
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only
Loading...
Loading...
Loading...